Retinal ganglion cell complex and visual evoked potentials in levetiracetam treatment

References

• Lyseng-Williamson KA. Levetiracetam: a review of its use in epilepsy. Drugs 2011;71:489–514.
   PubMed Web of Science ®Google Scholar
• Guerrini R. Epilepsy in children. Lancet 2006; 367:499–524.
   PubMed Web of Science ®Google Scholar
• Proposal for revised classification of epilepsies and epileptic syndromes: commission on Classification and Terminology of the International League Against Epilepsy. Epilepsia 1989;30:389–399.
   PubMed Web of Science ®Google Scholar
• National Institute for Clinical Excellence. Technology appraisal 76: newer drugs for epilepsy in adults. London: National Institute of Clinical Excellence, 2004.
   Google Scholar
• National Institute for Clinical Excellence. Technology appraisal 79: newer drugs for epilepsy in children. London: National Institute of Clinical Excellence, 2004.
   Google Scholar
• LaRoche SM. A new look at the second-generation antiepileptic drugs: a decade of experience. Neurologist 2007;13:133–139.
   PubMed Web of Science ®Google Scholar
• Hilton EJ, Hosking SL, Betts T. The effect of antiepileptic drugs on visual performance. Seizure 2004;13:113–128.
   PubMed Web of Science ®Google Scholar
• Korpi ER, Mattila MJ, Wisden W, et al. GABA(A)-receptor subtypes: clinical efficacy and selectivity of benzodiazepine site ligands. Ann Med. 1997;29:275–282.
   PubMed Web of Science ®Google Scholar
• Manners TD, Clarke MP. Maculopathy associated with diazepam. Eye 1995;9:660–662.
   PubMed Web of Science ®Google Scholar
• Hyams SW, Keroub C. Glaucoma due to diazepam. Am J Psychiatry 1997;134:447–448.
   Google Scholar
• Noachtar S, Von Maydell B, Fuhry L, et al. Gabapentin and carbamazepine affect eye movements and posture control differently: a placebo-controlled investigation of acute CNS side-effects in healthy volunteers. Epilepsy Res 1998; 31:47–57.
   PubMed Web of Science ®Google Scholar
• Lopez L, Thomson A, Rabinowicz AL. Assessment of colour vision in epileptic patients exposed to single-drug therapy. Eur Neurol 1999;41:201–205.
   PubMed Web of Science ®Google Scholar
• Kalis MM, Huff NA. Oxcarbazepine, an antiepileptic agent. Clin Ther 2001;23:680–700.
   PubMed Web of Science ®Google Scholar
• Fisher RS, Eskola J, Blum D, et al. Open label pilot study of oxcarbazepine for inpatients under evaluation for epilepsy surgery. Drug Dev Res 1996;38:43–49.
   Web of Science ®Google Scholar
• Bayer AU, Thiel HJ, Zrenner E, et al. Color vision test for the early detection of antiepileptic drug toxicity. Neurology 1997;48:1394–1397.
   PubMed Web of Science ®Google Scholar
• Harding GF, Wild JM, Robertson KA, et al. Electro-oculography, electroretinography, visual evoked potentials, and multifocal electroretinography in patients with vigabatrin-attributed visual field constriction. Epilepsia 2000;41:1420–1431.
   PubMed Web of Science ®Google Scholar
• Mervaala E, Partanen J, Nousianinen U, et al. Electrophysiologic effects of gamma-vinyl GABA and carbamazepine. Epilepsia 1989;30:189–193.
   PubMed Web of Science ®Google Scholar
• Verrotti A, Trotta D, Cutarella R, et al. Effects of antiepileptic drugs on evoked potentials in epileptic children. Pediatr Neurol 2000;23:397–402.
   PubMed Web of Science ®Google Scholar
• Geller AM, Hudnell HK, Vaughn BV, et al. Epilepsy and medication effects on the pattern visual evoked potential. Doc Ophthalmol 2005;110:121–131.
   PubMed Web of Science ®Google Scholar
• Zgorzalewicz M, Galas-Zgorzalewicz B. Visual and auditory evoked potentials during longterm vigabatrin treatment in children and adolescents with epilepsy. Clin Neurophysiol 2000;111:2150–2154.
   PubMed Web of Science ®Google Scholar
• Diler Durgut B, Turk A, Acar Arslan E, et al. An investigation of the ocular toxic effects of levetiracetam therapy in children with epilepsy. Childs Nerv Syst 2019;35:769–774.
   PubMed Web of Science ®Google Scholar
• Odom JV, Bach M, Brigell M, et al. ISCEV Standard for clinical visual evoked potentials: (2016 update). Doc Ophthalmol 2016;133:1–9.
   PubMed Web of Science ®Google Scholar
• Dereci S, Koca T, Akçam M, et al. An evaluation of peripapillary retinal nerve fiber layer thickness in children with epilepsy receiving treatment of valproic acid. Pediatr Neurol 2015;53:53–57.
   PubMed Web of Science ®Google Scholar
• Prokosch V, Eter N. Correlation between early retinal nerve fiber layer loss and visual field loss determined by three different perimetric strategies: white-on-white, frequency-doubling, or flickerdefined form perimetry. Graefes Arch Clin Exp Ophthalmol 2014;252:1599–1606.
   PubMed Web of Science ®Google Scholar
• Saxena R, Bandyopadhyay G, Singh D, et al. Evaluation of changes in retinal nerve fiber layer thickness and visual functions in cases of optic neuritis and multiple sclerosis. Indian J Ophthalmol 2013;61:562–566.
   PubMed Web of Science ®Google Scholar
• Arifoglu HB, Simavli H, Midillioglu I, et al. Comparison of ganglion cell and retinal nerve fiber layer thickness in pigment dispersion syndrome, pigmentary glaucoma, and healthy subjects with spectral-domain OCT. Semin Ophthalmol 2017;32:204–209.
   PubMed Web of Science ®Google Scholar
• Pazos M, Dyrda AA, Biarnés M, et al. Diagnostic accuracy of spectralis SD OCT automated macular layers segmentation to discriminate normal from early glaucomatous eyes. Ophthalmology 2017;124:1218–1228.
   PubMed Web of Science ®Google Scholar
• Vuong LN, Hedges TR. 3rd., Ganglion cell layer complex measurements in compressive optic neuropathy. Curr Opin Ophthalmol 2017;28:573–578.
   PubMed Web of Science ®Google Scholar
• Verrotti A, Manco R, Matricardi S, et al. Antiepileptic drugs and visual function. Pediatr Neurol 2007;36:353–360.
   PubMed Web of Science ®Google Scholar
• Aktas Z, Cansu A, Erdogan D, et al. Retinal ganglion cell toxicity due to oxcarbazepine and valproic acid treatment in rat. Seizure 2009; 18:396–399.
   PubMed Web of Science ®Google Scholar
• Göktas¸ G, Aktas Z, Erdogan D, et al. Ciliary body toxicities of systemic oxcarbazepine and valproic acid treatments: electron microscopic study. Cutan Ocul Toxicol 2014;28:1–5.
   Google Scholar
• Moseng L, Saeter M, Mørch-Johnsen GH, et al. Retinal nerve fibre layer attenuation: clinical indicator for vigabatrin toxicity. Acta Ophthalmol 2011;89:452–458.
   PubMed Web of Science ®Google Scholar
• Akçakaya AA, Gökçeer S, Erbil HH, et al. Detecting retinal vigabatrin toxicity in patients with partial symptomatic or cryptogenic epilepsy. Eur J Ophthalmol 2010;20:763–769.
   PubMed Web of Science ®Google Scholar
• Green JB, Walcoff MR, Lucke JF. Comparison of phenytoin and phenobarbital effects on far-field auditory and somatosensory evoked potential interpeak latencies. Epilepsia 1982;23:417–421.
   PubMed Web of Science ®Google Scholar
• Cosi V, Callieco R, Galimberti CA. Effect of Vigabatrin on evoked potentials in epileptic patients. Br J Clin Pharmacol 1989;27:61–68.
   Web of Science ®Google Scholar
• Drake ME, Pakalnis A, Padamadan H, et al. Effect of anti-epileptic drug monotherapy and polypharmacy on visual and auditory evoked potentials. Electromyogr Clin Neurophysiol 1989; 29:55–58.
   PubMedGoogle Scholar
• Chan YW, Woo E, Yu Y. Chronic effects of phenytoin on brain-stem auditory evoked potentials in man. Electroencephalogr Clin Neurophysiol 1990;77:119–126.
   PubMedGoogle Scholar
• Japaridze G, Kvernadze D, Geladre T, et al. Effects of carbamazepine on auditory brainstem response, middle-latency response, and slow cortical potential in epileptic patients. Epilepsia 1993;34:1105–1109.
   PubMed Web of Science ®Google Scholar
• Tumay Y, Altun Y, Ekmekci K, et al. The effects of levetiracetam, carbamazepine, and sodium valproate on P100 and P300 in epileptic patients. Clin Neuropharmacol 2013;36:55–58.
   PubMed Web of Science ®Google Scholar
• Kwiecińska P, Taubøll E, Gregoraszczuk EL. Comparison of the effects of valproic acid and levetiracetam on apoptosis in the human ovarian cancer cell line OVCAR-3. Pharmacol Rep 2012;64:603–614.
   PubMed Web of Science ®Google Scholar
• Kwiecińska P, Wiśniewska J, Gregoraszczuk EŁ. Effects of valproic acid (VPA) and levetiracetam (LEV) on proliferation, apoptosis and hormone secretion of the human choriocarcinoma BeWo cell line. Pharmacol Rep 2011;63:1195–1202.
   PubMed Web of Science ®Google Scholar
• Stettner M, Dehmel T, Mausberg AK, et al. Levetiracetam exhibits protective properties on rat Schwann cells in vitro. J Peripher Nerv Syst 2011;16:250–260.
   PubMed Web of Science ®Google Scholar
• Mohammad HMF, Sami MM, Makary S, et al. Neuroprotective effect of levetiracetam in mouse diabetic retinopathy: effect on glucose transporter-1 and GAP43 expression. Life Sci 2019;232:116588.
   PubMed Web of Science ®Google Scholar